A reduction in risk of a composite outcome of cardiovascular death, myocardial infarction and stroke in people with type 2 diabetes and established atherosclerotic cardiovascular disease with SGLT2 inhibitor use was evident in these cardiovascular outcome trials [11]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.